The European Union granted Zhejiang Tianyu Pharmaceutical (SHE:300702) the European Pharmacopoeia Certificate of Suitability for its formulation of telmisartan, according to a Wednesday filing with the Shenzhen bourse.
Telmisartan is indicated for hypertension and the reduction of cardiovascular risk, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments